[1] 陈亚进,商昌珍.肝内胆管细胞癌诊治策略. 中国实用外科杂志,2015,35(1):43-45. [2] Gruenberger B,Schueller J,Heubrandtner U,et al. Cetuximab, gemcitabine and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer:a phase 2 study. Lancet Oncol,2010,11(12):1142-1148. [3] Rubovszky G,Lang I,Ganofaszky E,et al. Cetuximab,gemcitabine and capecitabine in patients with inoperable biliary tract cancer:a phase 2 study. Eur J Cancer,2013,49(18):3806-3812. [4] Eckel F,Schmid RM. Chemotherapy in advanced biliary tract carcinoma:a pooled analysis of clinical trials. Br J Cancer,2007,96(6):896-902. [5] Kanekura T,Chen X,Kanzaki T. Basigin(CD147) is expressed on melanoma cells and induces tumor cell invasion by stimulating production of matrix metalloproteinases by fibroblasts. Int J Cancer,2002,99(4):520-528. [6] Dalberg K,Eriksson E,Enberg U,et al. Gelatinase A,membrane type 1 matrix metalloproteinases,and extracellular matrix metalloproteinases induce mRNA expression:correlation with invasive growth of breast cancer. World J Surg,2000,24(3):334-340. [7] Sun J,Hemler ME. Regulation of MMP-1 and MMP-2 production through CD147/extracellular matrix metalloproteinase induce interactions. Cancer Res,2001,61(5):2276-2281. [8] Khan SA,Thomas HC,Davidson Y,et al. Changiocarcinoma. Lancet,2005,366(9493):1303-1314. [9] Fava G,Marzioni M,Benedetti A,et al. Molecular pathology of biliary tract cancer. Cancer Lett,2007,250(2):155-167. [10] Poultsides GA,Zhu AX,Choti MA,et al. Intrahepatic cholangiocarainoma. Surg Clin North Am,2010,90(4):817-837. [11] Bekaii T,Phelps MA,Li X,et al. Multi-institutional phase Ⅱ study of selumetinib in patients with metastatic biliary cancer. J Clin Oncol,2011,29(17):2357-2363. [12] Bengala C,Bertolini F,Malavsi N,et al. Sorafenib in patients with advanced biliary tract carcinoma:a phase 2 trail. Br J Cancer,2010,102(1):68-72. [13] Yi JH,Thongprasert S,Lee J,et al. A phase 2 study of sunitinib as a second-line treatment in advanced biliary tract carcinoma:a multicenter,multinational study. Eur J Cancer,2012,48(2):196-201. [14] Amitcohen BC,Rahat MM,Rahat MA. Tumor cell macrophage interactions increase angiogenesis through secretion og EMMMPRIN. Front Physiol,2013,12(4),178-183. [15] Tang Y,Nakada MT,Rafferty P,et al. Regulation of vascular endothelial growth factor expression by EMMPRIN via the P13K-Akt signaling pathway. Mol Cancer Res,2006,4(6):371-377. [16] Biswas C,Zhang Y,DeCastro R,et al. The human tumor cell-derived collagenase stimulatory factor (renamed EMMPRIN) is a member of the immunoglobulin superfamily. Cancer Res,1995,55(2):434-439. [17] Mccawley LJ,Matrisian LM. Tumor progression: Defining the soil round the tumor seed. Curr Biol,2001,11(1):25-27. [18] Sidhu SS,Mengistab AT,Tauscher AN,et al. The microvesicle as a vehicle for EMMPRIN in tumor-stromal interactions. Oncogene,2004,23(4):956-963. [19] Li Y,Shang P,Qian AR,et al. Inhibitory effects of antisense RNA of HAb18G/CD147 on invasion of hepatocellular carcinoma cells in vitro. World J Gastroenterol,2003,9(10):2174-2177. [20] Chen ZN,Mi L,Xu J,et al. Targeting radioimmunotherapy of hepatocellular carcinoma with iodine(1311) metuximab injection:clinical phase I/II trials. Int J Radiat Oncol Biol Phys,2006,65(2):435-444. |